NSE filing, NSE: AARTIDRUGS. Summary written from the filing by ALFA Finder's alert engine.
Aarti Drugs Ltd: key numbers
- Share price
- ₹447.90
- Market cap
- ₹4,088 Cr
- Revenue (annual)
- ₹2,565 Cr
- Net profit (annual)
- ₹194.9 Cr
- P/E (TTM)
- 21.4×Sector 46.1×
- Promoter holding
- 54.07%-0.36% QoQ
- FII holding
- 2.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Drugs Ltd
All →Aarti Drugs Board Meeting Date
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
Aarti Drugs Other Announcement
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Aarti Drugs Other Announcement
Aarti Drugs has updated its list of authorized personnel for determining materiality of events and making stock exchange disclosures, effective October 1, 2026.
Aarti Drugs Management Change
Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.
Aarti Drugs Investor Presentation: Key Takeaways
Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.
Aarti Drugs Annual General Meeting
Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.